產(chǎn)品名稱 |
RPMI 8226 |
商品貨號(hào) |
B228624 |
Organism |
Homo sapiens, human |
Tissue |
peripheral blood |
Cell Type |
B lymphocyte (KRAS CRM) |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
plasmacytoma; myeloma |
Age |
61 years |
Gender |
male |
Applications |
For use in testing and calibration in ISO 17025 accredited laboratories, to challenge assay performance, validate or compare test methods, and to establish sensitivity, linearity and specificity during assay validation or implementation.
This cell line is a suitable transfection host. |
Intended Use |
Certified Reference Material produced under an ISO 17034 accredited process.
|
Storage Conditions |
liquid nitrogen vapor phase |
Karyotype |
Unstable karyotype in triploid range of 68-70 chromosomes. Two large marker chromosomes with terminal centromeres. |
Clinical Data |
male |
Antigen Expression |
HLA Aw19, B15, B37, Cw2; CD19 -; CD20 -; CD28 +; CD38 +; CD49e + |
Genes Expressed |
immunoglobulin light chain,HLA Aw19, B15, B37, Cw2; CD19 -; CD20 -; CD28 +; CD38 +; CD49e + |
Cellular Products |
immunoglobulin light chain |
Virus Susceptibility |
Human poliovirus 1
Herpes simplex virus
Vaccinia virus
Vesicular stomatitis virus
|
Comments |
Certificates of Analysis are available electronically at www.atcc.org, or by hardcopy upon request.
There is no evidence of heavy chain production (cytoplasmic or secreted).
Certified Reference Material produced under an ISO 17034 accredited process.
Item has been tested for KRAS mutation (p.G12A c.35G>C) |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 105 viable cells/mL. Do not allow the cell density to exceed 2 to 3 X 106 cells/mL.
Interval: Maintain cell density between 5 X 105 and 2 X 106 viable cells/mL.
Medium Renewal: Every 2 to 3 days |
Cryopreservation |
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage Temperature: Liquid nitrogen vapor phase |
Culture Conditions |
Atmosphere: Air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
STR Profile |
Amelogenin: X,Y CSF1PO: 12 D13S317: 11 D16S539: 9 D5S818: 11,13 D7S820: 9,10 THO1: 8 TPOX: 8,11 vWA: 16,18 |
Isoenzymes |
G6PD, A |
Isotype |
lambda light chain |
Year of Origin |
June, 1966 |
References |
Matsuoka Y, et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125: 1246-1250, 1967. PubMed: 6042436
Moore GE, Kitamura H. Cell line derived from patient with myeloma. N.Y. State J. Med. 68: 2054-2060, 1968. PubMed: 5243066
Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375
|